Proton pump inhibitors (PPIs) are the first‐line treatment for gastric acid‐related disorders such as peptic ulcer disease (PUD), gastroesophageal reflux disease (GERD), and non‐steroid anti‐inflammatory drug (NSAID)‐induced mucosal damage.1 This evidence concerns the gene ATP4A and gastroesophageal reflux disease.